MX2015005756A - Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4. - Google Patents
Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4.Info
- Publication number
- MX2015005756A MX2015005756A MX2015005756A MX2015005756A MX2015005756A MX 2015005756 A MX2015005756 A MX 2015005756A MX 2015005756 A MX2015005756 A MX 2015005756A MX 2015005756 A MX2015005756 A MX 2015005756A MX 2015005756 A MX2015005756 A MX 2015005756A
- Authority
- MX
- Mexico
- Prior art keywords
- her3
- hairpin
- beta
- her4
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
La invención se refiere a proteínas de unión a antígeno anti-HER3/HER4, por ejemplo anticuerpos anti-HER3/HER4, las cuales se unen a la horquilla beta de HER3 y a la horquilla beta de HER4, a métodos para seleccionar estas proteínas de unión a antígeno, y a su preparación y utilización como medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12191871 | 2012-11-08 | ||
PCT/EP2013/073093 WO2014072305A1 (en) | 2012-11-08 | 2013-11-06 | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015005756A true MX2015005756A (es) | 2015-09-16 |
Family
ID=47143739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015005756A MX2015005756A (es) | 2012-11-08 | 2013-11-06 | Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4. |
Country Status (20)
Country | Link |
---|---|
US (2) | US9725511B2 (es) |
EP (1) | EP2917242B1 (es) |
JP (2) | JP6537970B2 (es) |
KR (1) | KR20150063565A (es) |
CN (1) | CN104755499B (es) |
AR (1) | AR093778A1 (es) |
AU (1) | AU2013343666A1 (es) |
CA (1) | CA2884429A1 (es) |
CL (1) | CL2015001230A1 (es) |
CR (1) | CR20150195A (es) |
EA (1) | EA201500503A1 (es) |
HK (1) | HK1211598A1 (es) |
IL (1) | IL237790A0 (es) |
MA (1) | MA38164B1 (es) |
MX (1) | MX2015005756A (es) |
PE (1) | PE20150955A1 (es) |
PH (1) | PH12015500751A1 (es) |
SG (1) | SG11201502534UA (es) |
TW (1) | TWI519542B (es) |
WO (1) | WO2014072305A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201502534UA (en) * | 2012-11-08 | 2015-05-28 | Hoffmann La Roche | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
EA201500502A1 (ru) | 2012-11-08 | 2015-10-30 | Ф.Хоффманн-Ля Рош Аг | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 |
RU2016148682A (ru) * | 2014-05-14 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3 |
KR20170003572A (ko) | 2014-05-14 | 2017-01-09 | 에프. 호프만-라 로슈 아게 | Her3의 베타-헤어핀 및 her2의 도메인 ii에 결합하는 her3/her2 이중특이성 항체 |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
CN109022389A (zh) * | 2018-07-19 | 2018-12-18 | 陕西慧康生物科技有限责任公司 | 一种大肠杆菌表达人艾杜糖醛酸-2-硫酸酯酶的生产方法 |
US20220072144A1 (en) * | 2018-09-20 | 2022-03-10 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
WO2024077122A1 (en) * | 2022-10-05 | 2024-04-11 | The Regents Of The University Of California | Multipurpose, multi-functionalized lipid coated beads and methods of production |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3925943B2 (ja) | 1996-03-27 | 2007-06-06 | ジェネンテック インコーポレーテッド | ErbB3抗体 |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
ATE522603T1 (de) * | 2001-06-22 | 2011-09-15 | Hoffmann La Roche | Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält |
WO2003012072A2 (en) * | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
CA2510717C (en) | 2002-12-20 | 2010-11-02 | Elke Faatz | Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
EP1971684B1 (en) * | 2006-01-03 | 2011-10-05 | Roche Diagnostics GmbH | Chimaeric fusion protein with superior chaperone and folding activities |
US7897723B2 (en) | 2006-04-07 | 2011-03-01 | Københavns Universitet | ErbB receptor-derived peptide fragments |
KR20090031897A (ko) * | 2006-06-12 | 2009-03-30 | 리셉터 바이오로직스 인크 | 전-세포 표면 수용체-특이적 치료제 |
EP2129396B1 (en) | 2007-02-16 | 2013-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
ES2450998T3 (es) * | 2007-12-13 | 2014-03-26 | F. Hoffmann-La Roche Ag | Nuevas variantes de proteína de cubierta E1 de rubéola y su utilización en la detección de anticuerpos anti-rubéola |
SG174378A1 (en) | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
CA2757531A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-3/anti-c-met antibodies |
US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
EP3546483A1 (en) | 2010-05-20 | 2019-10-02 | Ablynx N.V. | Biological materials related to her3 |
PE20140230A1 (es) * | 2010-08-20 | 2014-02-26 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
JP2014527035A (ja) | 2011-06-30 | 2014-10-09 | メリマック ファーマシューティカルズ インコーポレーティッド | 婦人科悪性腫瘍を治療するためのパクリタキセルとの組み合わせの抗ErbB3抗体 |
IN2014CN03042A (es) | 2011-09-30 | 2015-07-03 | Regeneron Pharma | |
UY34487A (es) | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3) |
TW201328707A (zh) | 2011-12-05 | 2013-07-16 | Novartis Ag | 針對表皮生長因子受體3(her3)之區域ii之her3抗體 |
EA201500502A1 (ru) | 2012-11-08 | 2015-10-30 | Ф.Хоффманн-Ля Рош Аг | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 |
SG11201502534UA (en) * | 2012-11-08 | 2015-05-28 | Hoffmann La Roche | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
RU2016148682A (ru) | 2014-05-14 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3 |
-
2013
- 2013-11-06 SG SG11201502534UA patent/SG11201502534UA/en unknown
- 2013-11-06 KR KR1020157011989A patent/KR20150063565A/ko not_active Application Discontinuation
- 2013-11-06 MA MA38164A patent/MA38164B1/fr unknown
- 2013-11-06 WO PCT/EP2013/073093 patent/WO2014072305A1/en active Application Filing
- 2013-11-06 MX MX2015005756A patent/MX2015005756A/es unknown
- 2013-11-06 US US14/073,137 patent/US9725511B2/en active Active
- 2013-11-06 CA CA2884429A patent/CA2884429A1/en not_active Abandoned
- 2013-11-06 AU AU2013343666A patent/AU2013343666A1/en not_active Abandoned
- 2013-11-06 PE PE2015000609A patent/PE20150955A1/es not_active Application Discontinuation
- 2013-11-06 EA EA201500503A patent/EA201500503A1/ru unknown
- 2013-11-06 EP EP13789759.1A patent/EP2917242B1/en active Active
- 2013-11-06 CN CN201380056465.2A patent/CN104755499B/zh active Active
- 2013-11-06 JP JP2015540165A patent/JP6537970B2/ja not_active Expired - Fee Related
- 2013-11-06 AR ARP130104061A patent/AR093778A1/es unknown
- 2013-11-07 TW TW102140562A patent/TWI519542B/zh not_active IP Right Cessation
-
2015
- 2015-03-16 IL IL237790A patent/IL237790A0/en unknown
- 2015-04-06 PH PH12015500751A patent/PH12015500751A1/en unknown
- 2015-04-16 CR CR20150195A patent/CR20150195A/es unknown
- 2015-05-07 CL CL2015001230A patent/CL2015001230A1/es unknown
- 2015-12-11 HK HK15112242.4A patent/HK1211598A1/xx unknown
-
2017
- 2017-08-03 US US15/668,396 patent/US10364290B2/en not_active Expired - Fee Related
- 2017-11-06 JP JP2017213776A patent/JP2018068298A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20150955A1 (es) | 2015-06-20 |
CR20150195A (es) | 2015-05-18 |
AU2013343666A1 (en) | 2015-04-09 |
CL2015001230A1 (es) | 2015-07-10 |
US9725511B2 (en) | 2017-08-08 |
JP2015536336A (ja) | 2015-12-21 |
JP6537970B2 (ja) | 2019-07-03 |
SG11201502534UA (en) | 2015-05-28 |
US20180118837A1 (en) | 2018-05-03 |
TWI519542B (zh) | 2016-02-01 |
CA2884429A1 (en) | 2014-05-15 |
EP2917242A1 (en) | 2015-09-16 |
CN104755499B (zh) | 2020-10-02 |
CN104755499A (zh) | 2015-07-01 |
US10364290B2 (en) | 2019-07-30 |
EA201500503A1 (ru) | 2015-10-30 |
PH12015500751A1 (en) | 2015-05-25 |
MA38164B1 (fr) | 2018-11-30 |
US20140186354A1 (en) | 2014-07-03 |
IL237790A0 (en) | 2015-05-31 |
MA38164A3 (fr) | 2018-05-31 |
KR20150063565A (ko) | 2015-06-09 |
AR093778A1 (es) | 2015-06-24 |
TW201422641A (zh) | 2014-06-16 |
JP2018068298A (ja) | 2018-05-10 |
WO2014072305A1 (en) | 2014-05-15 |
HK1211598A1 (en) | 2016-05-27 |
EP2917242B1 (en) | 2018-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500751A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4 | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
EP3786183A3 (en) | Antigen binding constructs to cd3 | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
PH12015502293A1 (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
PH12014501108A1 (en) | Anti-il-36r antibodies | |
TN2015000247A1 (en) | Bcma antigen binding proteins | |
MX2014014162A (es) | Anticuerpos multiespecificos. | |
MX2012007340A (es) | Anticuerpos anti/her3 y usos de los mismos. | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
NZ703423A (en) | Antibodies to tau | |
MX348637B (es) | Anticuerpos y composiciones anti-her3. | |
UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
MX343659B (es) | Proteínas de unión receptoras fc. | |
EA201291065A1 (ru) | Антитела против vla-4 | |
HK1208474A1 (en) | Antigen binding proteins that bind egfr egfr | |
HK1214283A1 (zh) | 結合的抗原結合蛋白 | |
MX2016014416A (es) | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. | |
WO2013122544A3 (en) | IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
NZ743971A (en) | Antibodies to tau |